《中国期刊全文数据库》收录期刊
《中国核心期刊(遴选)数据库》收录期刊
《中文科技期刊数据库》收录期刊

Surgical Research and New Technique ›› 2019, Vol. 8 ›› Issue (4): 262-264.doi: 10.3969/j.issn.2095-378X.2019.04.012

• Original article • Previous Articles     Next Articles

Effects of tamoxifen and anastrazole endocrine therapies for breast canceron bone metabolism

WANG Yongliang, CHAI Hui, ZHAO Hongqing, WANG Huaijin, CHU Ruijun, GUO Siliang, ZHAI Yaojun   

  1. Department of Thyroid Breast, The First People’s Hospital of Yangquan City, Yangquan 045000, China
  • Received:2019-06-28 Online:2019-12-28 Published:2020-09-14

Abstract: Objective To observe the effects of tamoxifen and anatrazole endocrine therapies for breast cancer on bone metabolism.Methods A total of 150 patients with breast cancer who received endocrine therapy after radiotherapy were divided into anatrazole (ANA) group (n=75) and tamoxifen (TAM) group (n=75).All patients were treated for 12 months.The serum levels of calcitonin (CT), osteocalcin (BGP), and bone alkaline phosphatase (NBAP) were measured before and after treatment.The bone mineral density of L2-L4 was measured by X-ray absorptiometry.Results After treatment, the CT and NBAP of the two groups were higher than those before treatment, while the BGP and L2-L4 bone mineral density were lower (all P<0.01 or P<0.05).After treatment, the levels of CT, BGP, and NBAP in the ANA group were higher than those in the TAM group, while the L2-L4 bone mineral density was lower (P<0.01).Conclusion Both the endocrine therapies using TAM and ANA have significant effects on the levels of bone metabolism, especially ANA.

Key words: Tamoxifen, Anatrazole, Breast cancer, Endocrine therapy, Bone metabolism

CLC Number: